number share mn
chg prev ep
estimate pot chg tp
supplementari nda nmpa
outbreak subsid due faster-than-expect recoveri
compani may file soon expect approv
obtain within three month post-fil push approv
increas revenu forecast venusa-plu
mn mn due expedit approv timelin
maintain outperform lift tp
increas earn due faster approv
timelin venusa-plu increas tp
due venusa-plu higher revenu contribut higher
success rate adjust revenu tmvr/ttvr product candid
maintain outperform venu med-tech think
compani hold lead posit boom tavr market
china downsid risk includ delay regulatori approv
weaker-than-expect sale venusa-valv
may venu med-tech announc strateg partnership
opu medic therapi develop tmvr/ttvr product greater
china think tmvr/ttvr market blue sea market
patient base tavr partnership strengthen
venu posit tmvr/ttvr develop
increas success rate tmvr/ttvr product
thu increas success rate adjust revenu contribut
mn mn
updat target launch period venusa-plu
base channel check compani increas
revenu forecast venusa-plu mn mn
due expedit approv timelin
lift earn due faster approv
timelin venusa-plu increas tp due
venusa-plu higher revenu contribut higher success rate
tmvr/ttvr product develop maintain outperform
think compani hold lead posit boom tavr
market china
may venu med-tech announc strateg partnership
us base med-tech compani opu medic therapi develop
manufactur commercialis transcathet mitral/tricuspid valv
replac tmvr/ttvr product greater china opu
medic devic compani focus develop tmvr ttvr
product found member experi work abbott
mitraclip team believ partnership add valu
venu med-tech exist tmvr/ttvr product line allow venu
leverag opu expertis technolog platform tmvr/ttvr
product result increas success rate tmvr/ttvr
product increas success rate adjust revenu
contribut tmvr/ttvr mn
mn
tmvr/ttvr blue sea market china
china mitral valv diseas highest preval compar
heart valv diseas estim address
popul china may requir tmvr/ttvr procedur
mn peopl larger
address popul china may requir tavr
procedur combin patient base tavr current
commercialis tmvr/ttvr devic china
one tmvr/ttvr product candid clinic trial stage
think tmvr/ttvr market blue sea market
repres larg address popul signific unmet
medic need believ venu med-tech partnership opu
strengthen venu med-tech posit tmvr/ttvr
addit updat target launch period venusa-plu
base channel check compani
manag previous said
expect file
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
jason liu fei zheng certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
price rate histori venu med-tech
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
